An open-label study changing generic clozapine formulation to FazaClo (clozapine, USP) orally disintegrating tablets in stable patients with schizophrenia or schizoaffective disorder.

Trial Profile

An open-label study changing generic clozapine formulation to FazaClo (clozapine, USP) orally disintegrating tablets in stable patients with schizophrenia or schizoaffective disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Clozapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 28 Jul 2011 Planned end date changed from 1 Jan 2008 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top